Certara®, the global model-informed drug development and decision support leader, today reported that it has acquired a range of modeling and simulation technology assets from In Silico Biosciences, Inc. The assets include a platform of multiple integrated quantitative systems pharmacology (QSP) modules of brain physiology and pathology specifically developed for the study of neurodegenerative conditions, including Alzheimer’s, Parkinson’s and Huntington’s disease, which generally lack disease-modifying therapies. Certara’s Simcyp division is the undisputed leader in mechanistic modeling for QSP. The company’s QSP business model is based on its highly successful Simcyp Physiologically-based Pharmacokinetic (PBPK) Consortium, which is comprised of 37 leading biopharm companies and recently celebrated its 20-year anniversary and its enormous positive impact on drug development.
Read the full article: Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc. //
Source: https://www.businesswire.com/news/home/20200225005030/en/Certara%E2%80%99s-Simcyp-Division-Acquires-Modeling-Simulation-Platform